Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Denosumab/zoledronic-acid

Lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Patel R, et al. Bisphosphonate and Denosumab Refractory Hypercalcemia of Malignancy: What Else Is at Play?. Journal of the Endocrine Society 4 (Suppl.): A962 abstr. MON-335, May 2020. Available from: URL: https://dx.doi.org/10.1210/jendso/bvaa046.1908 [abstract] Patel R, et al. Bisphosphonate and Denosumab Refractory Hypercalcemia of Malignancy: What Else Is at Play?. Journal of the Endocrine Society 4 (Suppl.): A962 abstr. MON-335, May 2020. Available from: URL: https://​dx.​doi.​org/​10.​1210/​jendso/​bvaa046.​1908 [abstract]
Metadaten
Titel
Denosumab/zoledronic-acid
Lack of efficacy
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56799-y

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Amiodarone

Case report

Ethinylestradiol

Case report

Pyridostigmine